FDA Response on Zynquista™ Application
Lexicon Pharmaceuticals, Inc. recently received communication from the U.S. Food and Drug Administration (FDA) concerning their New Drug Application (NDA) for Zynquista™ (sotagliflozin). This drug was proposed as a complementary treatment alongside insulin therapy aimed specifically at improving glycemic control for adults suffering from type 1 diabetes and chronic kidney disease (CKD).
Company's Strategic Shift
This anticipated response from the FDA coincides with Lexicon's previous announcement about their strategic decision to halt launch preparations for Zynquista. The company's current focus is now firmly set on advancing its clinical development pipeline which promises to unveil innovative treatments for various health challenges.
Commitment to Ongoing Research
In a statement, Mike Exton, Ph.D., the CEO and director of Lexicon Pharmaceuticals, expressed gratitude towards those who participated in the clinical trials for Zynquista™ and the advocacy from the diabetes community seeking the drug's approval. He noted that while the outcome was not what the company had hoped for, there remains a strong dedication to pushing forward with their pipeline, which is poised to deliver transformative health solutions.
Focus on LX9211
Among the promising candidates in their pipeline is LX9211, specifically targeting diabetic neuropathic pain (DPNP). The company anticipates that top-line data from its PROGRESS Phase 2b study will be released soon, prompting optimism about the potential for new treatment avenues.
Innovative Approach to Drug Development
Lexicon Pharmaceuticals operates with a unique approach to drug discovery, driven by its Genome5000™ program. This pioneering genomics target discovery platform has been instrumental in the identification of over 100 protein targets that have significant therapeutic potential across various diseases. By leveraging these insights, Lexicon aims to develop innovative medicines that can effectively address unmet medical needs.
Diverse Therapeutic Pipeline
The company's portfolio includes promising drug candidates presently in various stages of discovery, clinical, and preclinical development, focusing not only on diabetic neuropathic pain but also on hypertrophic cardiomyopathy (HCM), obesity, metabolism, and several other indications.
Investors and Future Outlook
Lexicon's ongoing research efforts and strategic pivots have placed the company in a favorable position to impact the medical landscape significantly. Investors and stakeholders can look forward to upcoming data releases and advancements that aim to reinforce Lexicon's commitment to pioneering transformative treatments. As the company evaluates its trajectory following the FDA's response, it remains vigilant in its pursuit of developing safe and effective solutions for complex health challenges.
Contacting Lexicon Pharmaceuticals
For more detailed inquiries regarding investments or corporate information, stakeholders can reach out through established channels. Lisa DeFrancesco is available for investor relations, while Sheryl Seapy manages media communications ensuring transparency and engaging dialogue.
Frequently Asked Questions
What is the significance of the FDA's complete response letter?
The FDA's complete response letter indicates that additional information is required before Zynquista can move toward approval for market launch.
What is Zynquista™ (sotagliflozin) used for?
Zynquista™ is intended to be used as an adjunct therapy to improve glycemic control in adults managing type 1 diabetes alongside chronic kidney disease.
What are Lexicon’s next steps after the FDA response?
Lexicon plans to redirect its efforts towards enhancing the clinical development of its pipeline, particularly focusing on LX9211 for diabetic neuropathic pain.
How does Lexicon identify drug targets?
Through its Genome5000™ program, Lexicon utilizes a unique genomics target discovery platform that facilitates the identification of therapeutically relevant protein targets.
How can I get in touch with Lexicon Pharmaceuticals?
For investor inquiries, you can contact Lisa DeFrancesco at Lexicon Pharmaceuticals via their investor relations email.
